Antiallodynic effects of a CCKB antagonist in rats with nerve ligation injury: role of endogenous enkephalins - PubMed (original) (raw)

Antiallodynic effects of a CCKB antagonist in rats with nerve ligation injury: role of endogenous enkephalins

M L Nichols et al. Neurosci Lett. 1996.

Abstract

Cholecystokinin (CCK) may act as an endogenous anti-opioid and blockade of CCK receptors can enhance the potency and efficacy of morphine. This effect is blocked by opioid delta (delta) receptor antagonists, suggesting a tonic inhibitory action of CCK to diminish the release and/or availability of endogenous enkephalins. The present studies have further evaluated this possibility by studying the antiallodynic actions of a CCKB antagonist (L365,260) alone, or in the presence of thiorphan (a neutral endopeptidase inhibitor) in a model of peripheral neuropathy. Animals subjected to nerve injury, but not sham controls, exhibited long lasting, stable mechanical allodynia. Intrathecal (i.t.) administration of L365,260 or thiorphan alone did not alter allodynia. However, co-administration of these compounds produced a significant antiallodynic action which was antagonized by receptor selective doses of naltrindole, an opioid delta receptor antagonist. In addition, antisera to [Leu5]enkephalin, but not to [Met5]enkephalin, also blocked the antiallodynic action of thiorphan plus L365,260. These data suggest that blockade of CCKB receptors may enhance the actions or availability of endogenous [Leu5]enkephalin or a like substance which can elicit a significant antiallodynic action via opioid delta receptors when its degradation is by inhibited by thiorphan. The data suggest that delta opioids are involved in regulation of some aspects of nerve-injury induced pain.

PubMed Disclaimer

Cited by

Effect of naltrexone on neuropathic pain in mice locally transfected with the mutant μ-opioid receptor gene in spinal cord.
Kao JH, Gao MJ, Yang PP, Law PY, Loh HH, Tao PL. Kao JH, et al. Br J Pharmacol. 2015 Jan;172(2):630-41. doi: 10.1111/bph.12790. Br J Pharmacol. 2015. PMID: 24866991 Free PMC article.
Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain.
Olson KM, Lei W, Keresztes A, LaVigne J, Streicher JM. Olson KM, et al. Yale J Biol Med. 2017 Mar 29;90(1):97-110. eCollection 2017 Mar. Yale J Biol Med. 2017. PMID: 28356897 Free PMC article. Review.
The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation.
Petraschka M, Li S, Gilbert TL, Westenbroek RE, Bruchas MR, Schreiber S, Lowe J, Low MJ, Pintar JE, Chavkin C. Petraschka M, et al. Neuroscience. 2007 Jun 8;146(4):1795-807. doi: 10.1016/j.neuroscience.2007.03.029. Epub 2007 Apr 30. Neuroscience. 2007. PMID: 17467916 Free PMC article.
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, Patel SJ, Crysdale NY, Harrison JA, Maier SF, Rice KC, Watkins LR. Hutchinson MR, et al. Eur J Neurosci. 2008 Jul;28(1):20-9. doi: 10.1111/j.1460-9568.2008.06321.x. Eur J Neurosci. 2008. PMID: 18662331 Free PMC article.
Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.
Hanlon KE, Herman DS, Agnes RS, Largent-Milnes TM, Kumarasinghe IR, Ma SW, Guo W, Lee YS, Ossipov MH, Hruby VJ, Lai J, Porreca F, Vanderah TW. Hanlon KE, et al. Brain Res. 2011 Jun 13;1395:1-11. doi: 10.1016/j.brainres.2011.04.024. Epub 2011 Apr 20. Brain Res. 2011. PMID: 21550594 Free PMC article.

Antiallodynic effects of a CCKB antagonist in rats with nerve ligation injury: role of endogenous enkephalins - PubMed (original) (raw)